ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDERS TO AID PUBLIC COMMENT

In the Matter of Becton, Dickinson and Company and C. R. Bard
File No. 171 0140, Docket No. C-4637

I. INTRODUCTION

The Federal Trade Commission ("Commission") has accepted, subject to final approval,

professionals, extended care facilities, and other medical facilities throughout the world. Its

Bard and BD are the two largest manufacturers of soft tissue core needle biopsy devices in the United States, with a combined market share of 60% or greater. Other participants in the market include Cook Medical, Argon Medical Devices, Inc., and Hologic, Inc., but each of these manufacturers has a smaller market share than either Bard or BD. In addition, there is a fringe of other manufacturers with very small market shares.

C. The Relevant Geographic Market

The relevant geographic market for both tunneled home drainage catheter systems and soft tissue core needle biopsy devices is the United States. These relevant products are medical devices regulated by the U.S. Food and Drug Administration ("FDA"). Medical devices sold outside of the United States, but not approved for sale in the United States, are not viable competitive alternatives for U.S. consumers.

IV. COMPETITIVE EFFECTS OF THE TRANSACTION

The proposed Acquisition would likely substantially lessen competition in the sl(6(r)(e))4(i(y)20( )]TJ 0